[{"orgOrder":0,"company":"PharmaMar","sponsor":"Adium Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"||Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Adium Pharma","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Adium Pharma"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"||Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"||Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trabectedin","moa":"||Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"PharmaMar","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Trabectedin","moa":"||Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ STADA Arzneimittel"},{"orgOrder":0,"company":"PharmaMar","sponsor":"TOYO Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"||Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ TOYO Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ TOYO Pharmaceutical"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trabectedin","moa":"||Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Key Oncologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"||Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmaMar \/ Key Oncologics","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Key Oncologics"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Onko Kocsel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"||Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmaMar \/ Onko Kocsel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Onko Kocsel Pharmaceuticals"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trabectedin","moa":"||Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trabectedin","moa":"||Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Universit\u00e4t M\u00fcnster","sponsor":"Anturec Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trabectedin","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Universit\u00e4t M\u00fcnster","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Universit\u00e4t M\u00fcnster \/ Anturec Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Universit\u00e4t M\u00fcnster \/ Anturec Pharmaceuticals"},{"orgOrder":0,"company":"UNICANCER","sponsor":"PharmaMar | Ligue contre le cancer | National Research Agency, France | University Hospital Marseille | Institut Claudius Regaud | Institut Bergoni\u00e9 | Oncopole","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"||DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"UNICANCER","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"UNICANCER \/ PharmaMar | Ligue contre le cancer | National Research Agency, France | University Hospital Marseille | Institut Claudius Regaud | Institut Bergoni\u00e9 | Oncopole","highestDevelopmentStatusID":"8","companyTruncated":"UNICANCER \/ PharmaMar | Ligue contre le cancer | National Research Agency, France | University Hospital Marseille | Institut Claudius Regaud | Institut Bergoni\u00e9 | Oncopole"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trabectedin","moa":"||Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trabectedin","moa":"||Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Italian Sarcoma Group","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trabectedin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Italian Sarcoma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Italian Sarcoma Group \/ PharmaMar","highestDevelopmentStatusID":"8","companyTruncated":"Italian Sarcoma Group \/ PharmaMar"},{"orgOrder":0,"company":"Italian Sarcoma Group","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trabectedin","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Italian Sarcoma Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Italian Sarcoma Group \/ PharmaMar","highestDevelopmentStatusID":"10","companyTruncated":"Italian Sarcoma Group \/ PharmaMar"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"SON-1010","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Trabectedin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Trabectedin,Inapplicable

                          Therapeutic Area : Oncology

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : EVER Pharma has received the EU-wide marketing authorization of Trabectedin EVER Pharma, which is available in 0.25mg and 1mg vial sizes for treating advanced soft tissue sarcoma and ovarian cancer.

                          Product Name : Trabectedin EVER Pharma

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 22, 2024

                          Lead Product(s) : Trabectedin,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Ever Pharma CB

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : SON-1010 (IL12-FHAB) is a immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          January 21, 2025

                          Lead Product(s) : SON-1010,Trabectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          UNICANCER

                          Country arrow
                          EPSC
                          Not Confirmed

                          UNICANCER

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Doxorubicin Hydrochloride,Trabectedin

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : PharmaMar | Ligue contre le cancer | National Research Agency, France | University Hospital Marseille | Institut Claudius Regaud | Institut Bergonié | Oncopole

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          July 29, 2024

                          Lead Product(s) : Doxorubicin Hydrochloride,Trabectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : PharmaMar | Ligue contre le cancer | National Research Agency, France | University Hospital Marseille | Institut Claudius Regaud | Institut Bergonié | Oncopole

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cancer.

                          Product Name : Yondelis

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 11, 2023

                          Lead Product(s) : Trabectedin,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Johnson & Johnson Innovative Medicine

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Yondelis (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, that acts a DNA inhibitor. It is indicated for the treatment of of patients with unresectable or metastatic liposarcoma or leiomyo...

                          Product Name : Yondelis

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 11, 2023

                          Lead Product(s) : Trabectedin,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Johnson & Johnson Innovative Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Yondelis (trabectedin) binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix triggering a cascade of events like DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell d...

                          Product Name : Yondelis

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 17, 2023

                          Lead Product(s) : Trabectedin,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cancer.

                          Product Name : Yondelis

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 12, 2022

                          Lead Product(s) : Trabectedin,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Johnson & Johnson Innovative Medicine

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          08

                          Universität Münster

                          Country arrow
                          EPSC
                          Not Confirmed

                          Universität Münster

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 28, 2022

                          Lead Product(s) : Trabectedin,Ttf-Ngr

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Anturec Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Yondelis-Generic (trabectedin) is a DNA inhibitor, small molecule drug candidate. It is being developed for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.

                          Product Name : Yondelis-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 18, 2022

                          Lead Product(s) : Trabectedin,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The Therapeutic Goods Administration has approved the use of YONDELIS (trabectedin), marketed by Specialised Therapeutics, "for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-con...

                          Product Name : Yondelis

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 23, 2021

                          Lead Product(s) : Trabectedin,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank